Reports

KB Home reported Q1 2025 revenue of $1.39 billion, a 5% decrease year-over-year, with homes delivered down 9% to 2,770 units. The average selling price rose 4% to $500,700. Net income decreased 21% to $109.6 million, and the backlog value declined 21% to $2.20 billion. The company continues to face affordability challenges and slower buyer decision-making but remains focused on adjusting to market conditions.

• Revenue of $1.39 billion, down 5% from Q1 2024.
• Homes delivered decreased 9% to 2,770 units.

Oklo reported strong progress in Q4 2024, securing key agreements including a 12 GW Master Power Agreement with Switch and expanding its customer pipeline to 14 GW. While the company is still pre-revenue and reported a loss from operations, its regulatory advancements and strategic partnerships position it well for future deployment and revenue generation.

• Secured a 12 GW Master Power Agreement with Switch, one of the largest corporate power agreements in history.
• Expanded customer pipeline to approximately 14 GW, primarily driven by AI data center demand.

Enerpac Tool Group reported Q2 2025 net sales of $145.5 million, a 5.1% increase year-over-year, driven by 4.4% growth in Industrial Tools & Services. The company achieved an adjusted operating profit margin of 21.4% and an adjusted EBITDA margin of 23.2%. Net income rose to $20.9 million with EPS of $0.38, and the company maintained a low net debt to adjusted EBITDA ratio of 0.5x.

• Net sales of $145.5 million, up 5.1% year-over-year.
• Adjusted EBITDA margin of 23.2% despite gross margin pressure.

In Q4 2024, Centessa reported no revenue and a net loss of $111.3 million, a significant increase from the $36.8 million loss in Q4 2023. The loss was driven by a $34.1 million non-recurring charge related to debt extinguishment and a $31.5 million charge related to the discontinued SerpinPC program. R&D expenses rose to $60.9 million and G&A expenses reached $13.7 million. Adjusted EPS excluding the debt extinguishment loss was -$0.58 + $0.26 = -$0.32.

• No revenue was reported for Q4 2024, compared to $6.85 million in Q4 2023.
• Net loss widened to $111.3 million, including a $34.1 million non-recurring debt extinguishment loss.

Aura Biosciences posted a Q4 2024 net loss of $25.8 million, with no reported revenue. The company continued investing in clinical trials and manufacturing for its lead candidate bel-sar, resulting in higher R&D and G&A expenses. Cash and marketable securities totaled $151.1 million, expected to fund operations into the second half of 2026.

• EPS for Q4 2024 was -$0.52, missing estimates by $0.08.
• Net loss reached $25.8M, up from $22.1M in Q4 2023.

Sagimet Biosciences had a productive 2024, initiating its Phase 3 denifanstat program for MASH and receiving Breakthrough Therapy designation from the FDA. The company also advanced its second FASN inhibitor, TVB-3567, into clinical trials for acne. Financially, Sagimet reported a net loss of $16.2 million for Q4 2024, with increased research and development expenses.

• Sagimet initiated its Phase 3 denifanstat program for MASH in Q4 2024, with patient screening expected to begin in 1H 2025.
• Denifanstat received Breakthrough Therapy designation from the FDA for MASH, supported by positive Phase 2b FASCINATE-2 results.

The Oncology Institute achieved $100 million in revenue for Q4 2024, representing a 16.9% year-over-year increase. Dispensary revenue saw significant growth, while patient services declined due to the loss of a major contract. The company reported a net loss of $13.2 million for the quarter and continues to improve operational efficiency and cash flow.

• Generated $100 million in revenue, up 16.9% from Q4 2023.
• Patient services revenue declined 10.6% year-over-year due to a lost contract.

Lyra Therapeutics reported a net loss of $11.0 million for the fourth quarter of 2024, an improvement from $15.1 million in the same period last year. The company's total operating expenses decreased to $97.882 million from $68.678 million in the prior year, primarily due to reduced clinical and employee-related costs. Cash and cash equivalents stood at $40.6 million, sufficient to fund operations into Q1 2026.

• Net loss for Q4 2024 was $11.0 million, a decrease from $15.1 million in Q4 2023.
• Total operating expenses for Q4 2024 were $97.882 million, an increase from $68.678 million in Q4 2023.